Table 1 Clinical and demographic characteristics of the enrolled patients related to the presence of complications
Patients without complications N = 136 | Patients with complications N = 65 | p-value | ||
|---|---|---|---|---|
Median (IQR), Age | 40 (29–57) | 49 (31.0–65.0) | 0.02 | |
Male, n (%) | 96 (70.6%) | 37(56.9%) | 0.06 | |
Median (IQR) BMI | 21.3 (18-8-24.0) | 20.8 (19.6–23.4) | 0.60 | |
Ethnicity, n (%) | Caucasian | 62 (45.9) | 33 (50.8) | 0.59 |
Hispanic | 21 (15.6) | 6 (9.2) | ||
Asian | 30 (22.2) | 13 (20.0) | ||
African | 22 (16.3) | 13 (20.0) | ||
Smoking history, n (%) | Never smoker | 26/58 (44.8) | 9/29 (31.0) | 0.21 |
Former smoker | 5/58 (8.6) | 6/29 (20.7) | ||
Active smoker | 27/58 (46.6) | 14/29 (48.3) | ||
Pack/years | Mean (SD) | 44 (38.8) | 26.1 (23.4) | 0.29 |
Tuberculosis (disease status at diagnosis), n (%) | First episode | 126 (92.6) | 62 (95.4) | 0.46 |
Relapse | 10 (7.4) | 3 (4.6) | ||
Tuberculosis (pharmacological resistance), n (%) | Sensitive | 128 (94.1) | 61 (93.9) | 0.33 |
Mono-resistant 1 | 4 (2.9) | 2 (3.1) | ||
RR | 1 (0.07) | 0 (0.0) | ||
XDR | 0 (0.0) | 1 (1.5) | ||
MDR | 0 (0) | 1 (1.5) | ||
Dual mono-resistance | 3 (2.2) | 0 (0.0) | ||
HIV, n (%) | 6/131 (4.6) | 5/63 (7.9) | 0.34 | |
Haematological malignancy, n (%) | 1/131 (0.7) | 3/63 (4.65) | 0.10 | |
Solid malignancy, n (%) | 6/131 (4.4%) | 2/63 (3.1%) | 1.00 | |
Autoimmune diseases, n (%) | 2/131 (1.5%) | 2/63 (3.1%) | 0.59 | |
Chronic renal failure, n (%) | 3/131 (2.2) | 7/63 (10.8) | 0.01 | |
Diabetes mellitus, n (%) | 17/131 (12.5) | 6/63 (9.4) | 0.52 | |
Chronic liver disease, n (%) | 4/131 (4.4) | 7/63 (10.9) | 0.12 | |
Chronic lung disease, n (%) | 11/131 (8.1) | 11/63 (16.9) | 0.09 | |
Chronic heart disease, n (%) | 8/131 (12.9) | 11/63 (16.9) | 0.02 | |
Immunomodulatory therapy (i.e. corticosteroids, immunosuppressants; chemotherapy) > 1 month, n (%) | 3/131 (2.2%) | 5/63 (7.8%) | 0.06 | |